Results · Apr-Jun 2026
Hester Biosciences Q1 FY27 results
Sales fell 8% to ₹77.2 crore from ₹84.1 crore in Apr-Jun 2025.
Operating profit fell 0% to ₹22.8 crore, an operating margin of 29.5% (up 2.4 points from a year ago).
Net profit grew 459% to ₹96.7 crore from ₹17.3 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −23%, net profit +485%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 77.2 | 84.1 | −8% |
| Operating profit (EBITDA) | 22.8 | 22.8 | −0% |
| Operating margin | 29.5% | 27.1% | +2.4 pts |
| Net profit | 96.7 | 17.3 | +459% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.